Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...
HKG: 1801
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME
China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...
Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...
Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
China-based Innovent Biologics, Inc. (HKG: 1801) released its 2024 financial report, highlighting a robust growth...
Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
Innovent Biologics Doses First Patient with IBI354 in HeriCare-Ovarian01 Study
China-based Innovent Biologics, Inc. (HKG: 1801) has administered the first dose of its antibody-drug conjugate...
HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial
Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease
China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...
Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment
China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...
Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...
Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches
China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...
Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...
Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer
China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...
Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...